seed
Stage
1
Investors
About
BiPER Therapeutics develops first-in-class selective BiP inhibitors as targeted therapy for cancer patients, focusing on pushing cancer cells to burn out through unresolved ER stress induction.
Explore BiPER Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.